Global Trispecific Antibody Market Opportunity And Clinical Trials Insight 2028 Report Analysis and Data Highlights:
- Research Methodology
- Global Market Analysis
- Global Trispecific Antibody Market Opportunity Assessment: > USD 2 Billion
- US To Dominate Trispecific Antibodies Market: >70%
- Market and Drug Sales Insight 2024 Till 2028
- Future Market Assessment By Indication Till 2028
- Ongoing Clinical Trials Assessment by Status, Phase and Region
- Key Market Dynamics
- Competitor Landscape
Download Global Trispecific Antibody Market Opportunity & Clinical Trials Insight 2028 Report:
In last few years, therapeutic monoclonal antibodies have been well-established as biologics and are among the widely used therapeutics. The success as therapeutics is mainly attributable to several factors including safety profiles, physical and chemical properties. The resounding therapeutic success of monoclonal antibodies and advancement in the field of engineering methods, researchers have developed several multi-specific antibodies including bispecifics and trispecifics which are largely present in clinical development. These have shown promising results due to their tendency to bind more targets antigens, thus enhancing efficacy.
Trispecific antibodies are novel class of therapeutic antibodies which has the ability to bind three target antigens. The main application is in the field of cancer, in which one of three specificities is intended to redirect T or NK cells, and the other two targeting tumor associated antigens or tumor neoantigens, which are critical for the progression of cancer. Continuous research in this sector has led to the development of several formats including trispecific killer cell engagers (TriKE), trispecific NK cell engagers, trispecific T-cell activation constructs, and several others which have shown promising preclinical and clinical data.
GTB-3550 is one of the leading trispecific antibody construct developed by GT Biopharma. GTB3550 is a single chain trispecific recombinant fusion protein conjugate composed of the variable regions of the heavy and light chains of anti-CD16 and anti-CD33 antibodies, and a modified form of interleukin-15 (IL-15). The IL-15 provides a more sustainable signal that activates NK cell and enhances its ability to kill tumor cells. Currently, it is present in phase-I/II studies for the management of CD33 positive acute myeloid leukemia, myelodysplastic syndrome, and other hematopoetitc malignancies. The preliminary results have demonstrated that the novel trispecific antibody construct was well-tolerated and more than 50% patients experienced significant reduction in tumor growth. Apart from this, the company is also developing other trispecific constructs including GTB4550 and GTB5550 for solid tumors.
The increased interest in trispecific antibodies and fusion proteins is mainly driven by their potential to be both more precisely targeted and more potent that conventional monoclonal antibodies. The close proximity of the binding sites can lead to the formation of new complexes and trigger new cellular contacts. With three sites for interaction with the target cells, more targeted binding can be achieved and additional immune responses can be activated that involve the T-Cells and natural killer cells, leading to greater targeted cytotoxic effects.
Desite promising results, several factors limit their growth into market. The complexity of mulispecific antibodies and recombinant protein molecules can create process development and manufacturing challenges both from an expression and process standpoint. In addition, stringent regulatory norms and long process for drug development will also restrain its growth in market. However, several pharmaceutical giants have come together in collaboratin or partnerships to adopt new technologies and secure their position in market. The major companies working in global trispecific antibody market are GT Biopharma, Numab Therapeutics, Harpoon Therapeutics, Sanofi, and several others. </p.
Contact:
Neeraj Chawla
Research Head
+91-9810410366
